Discontinuation report SKYRIZI
| Report ID | 248607 |
| Drug Identification Number | 02487454 |
| Brand name | SKYRIZI |
| Common or Proper name | Risankizumab |
| Company Name | ABBVIE CORPORATION |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | RISANKIZUMAB |
| Strength(s) | 75MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 2 x 75mg/0.83 mL Syringe |
| ATC code | L04AC |
| ATC description | |
| Reason for discontinuation | Other (Please describe in comments) |
| Anticipated discontinuation date | 2024-12-16 |
| Actual discontinuation date | 2024-12-16 |
| Remaining supply date | 2023-09-01 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | The shortage was posted in 2023. No replenishment was received since then. Refer to the shortage posting for details. The company decision to discontinue was made at the end of 2024. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 8401 TRANS-CANADA HIGHWAY SAINT-LAURENT, QUEBEC CANADA H4S 1Z1 |
| Company contact information | Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v10 | 2025-02-06 | French | Compare |
| v9 | 2025-02-06 | English | Compare |
| v8 | 2025-02-04 | English | Compare |
| v7 | 2025-01-27 | English | Compare |
| v6 | 2025-01-27 | French | Compare |
| v5 | 2025-01-27 | English | Compare |
| v4 | 2025-01-27 | French | Compare |
| v3 | 2025-01-27 | English | Compare |
| v2 | 2025-01-27 | English | Compare |
| v1 | 2025-01-27 | English | Compare |
Showing 1 to 10 of 10